Shantha Biotech starts Rs.250-cr unit in Hyderabad
Sharath Chowdary Shantha Biotechnics has started commercial production of its new manufacturing unit in Muppireddipalli Special Economic Zone (SEZ) near Hyderabad. With an investment of over Rs.250 crore, the new facility has been built to produce and export vaccines to the United Nations Children's Emergency Fund (UNICEF) and other international markets. The company is completely owned by Sanofi Pasteur, the vaccines division of French pharma company Sanofi Group. Another manufacturing facility is also being set up in Hyderabad with an investment of Rs.450 crore for the production of Insuman, human insulin, used in the treatment of diabetes. This plant is expected to commence its operations next year, Varaprasad Reddy, Chairman of Shantha Biotechnics told The Dollar Business. He said, “The two facilities are ...
